Term
|
Definition
| a1 (a2, ß1) vasoconstriction to increase BP; reflex bradycardia decreases HR |
|
|
Term
|
Definition
| ß1 increase HR and contractile force to increase CO (increase SBP); ß2 bronchodilation, hyperglycemia (increase gluconeogenesis and glycogenolysis), lipolysis, (decrease DBP so overall no BP change); (a1,a2) |
|
|
Term
|
Definition
| ß1 increase HR and contractile force to increase CO (increase SBP w/relex decrease PR so overal BP decrease); ß2 bronchodilation |
|
|
Term
|
Definition
| D1 (@low dose) renal vasodilation increase BF to kindey and increase in renal function; ß1 (@ medium dose) increase HR and contractile force to increase CO with reflex BP drop; a1 (@ high dose) vasoconstriction with increase in BP |
|
|
Term
|
Definition
| ß1 increase HR and contractile force to increase CO w/minimal increase in BP |
|
|
Term
|
Definition
| a2 in CNS, potent decrease in SNS output and BP decrease |
|
|
Term
|
Definition
| a1 vasoconstriction increases BP with reflex decrease in HR, decreases BF to most vascular beds |
|
|
Term
|
Definition
| a2 in CNS, potent decrease in SNS output and BP decrease |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| blocks NE re-uptake into nerve terminals by blocking UPTAKE 1 |
|
|
Term
|
Definition
| releases NE from adrenergic neurons; metabolized my MAO to inactivate |
|
|
Term
|
Definition
| releases NE from adrenergic neurons; weak direct a and ß agonist; weakly blocks UPTAKE 1 b/c competes for uptake |
|
|
Term
|
Definition
| direct ß2 agonist; releases NE |
|
|
Term
|
Definition
| a1 agonist; slight ß2 agonist; slight NE releasing affects |
|
|
Term
|
Definition
| blocks tyrosine hydroxylase (rate-limiting step of NE synthesis) |
|
|
Term
|
Definition
| uses UPTAKE 1 to enter adrenergic neurons; initially blocks NE release by inhibiting Ca2+ channels; long term use depletes NE from storage vesicles |
|
|
Term
|
Definition
| diffuses into adrenergic neuron; depletes NE; inhibits UPTAKE 1 |
|
|
Term
|
Definition
| competitive irreversible a1 and a2 antagonist |
|
|
Term
|
Definition
| competitive reversible a1 and a2 antagonist |
|
|
Term
|
Definition
| selective competitive reversible a1 antagonist |
|
|
Term
|
Definition
| non-selective competitive reversible ß1 and ß2 antagonist |
|
|
Term
|
Definition
| non-selective competitive reversible ß1 and ß2 antagonist |
|
|
Term
|
Definition
| selective competitive reversible ß1 antagonist |
|
|
Term
|
Definition
| ultra-short acting selective competitive reversible ß1 antagonist |
|
|
Term
|
Definition
| non-selective competitive reversible ß1, ß2, and a1 antagonist; anti-oxidant properties |
|
|
Term
|
Definition
| muscarinic agonist resistant to degradation by acetylcholinesterase, so longer duration of action |
|
|
Term
|
Definition
| constriction of circular iris m. to open up angle to canal of schlemn (narrow); constriction of ciliary m. to promote drainage by better aligning obstructed canal (wide) |
|
|
Term
|
Definition
| rapid onset, short duration of action |
|
|
Term
|
Definition
| substrate hydrolyzed at a slow rate |
|
|
Term
|
Definition
| substrate hydrolyzed at a slow rate |
|
|
Term
|
Definition
| organophosphate acetylcholinesterase inhibitor; phosphorylates the serine in the substrate-binding domain |
|
|
Term
|
Definition
| organophosphate acetylcholinesterase inhibitor; phosphorylates the serine in the substrate-binding domain |
|
|
Term
|
Definition
| organophosphate acetylcholinesterase inhibitor; phosphorylates the serine in the substrate-binding domain |
|
|
Term
|
Definition
| blocks uptake of choline into nerve terminals (rate-limiting step of Ach synthesis) |
|
|
Term
|
Definition
| prevents release of Ach by cleaving vesicle/membrane tethering proteins |
|
|
Term
|
Definition
| reactivates enzyme inactivated by organophosphate inhibitors |
|
|
Term
|
Definition
| reversible competitive muscarinic receptor antagonist |
|
|
Term
|
Definition
| reversible competitive muscarinic receptor antagonist |
|
|
Term
|
Definition
| reversible competitive muscarinic receptor antagonist |
|
|
Term
|
Definition
| post-ganglion nerve blocker of both SNS and PNS |
|
|
Term
|
Definition
| non-depolarizing competitve antagonist |
|
|
Term
|
Definition
| non-depolarizing competitve antagonist |
|
|
Term
|
Definition
| non-depolarizing competitve antagonist |
|
|
Term
|
Definition
| non-depolarizing competitve antagonist |
|
|
Term
|
Definition
| depolarizing blockade b/c opens Ca2+ channels on endplate; dimer of 2 Ach molecules; produces muscle fasciculations and flaccid paralysis |
|
|
Term
| lysergic acid diethylamide |
|
Definition
| potent visual hallucinations |
|
|
Term
|
Definition
| vasocontriction of inflammed/dilated cerebral vasculature |
|
|
Term
|
Definition
| GI smooth muscle constriction to stimulate motility and stimulates intestinal secrestions |
|
|
Term
|
Definition
| selective serotonin reuptake inhibitor (SSRI) causing increase serotonin |
|
|
Term
|
Definition
| MAO inhibitor, blocks serotonin metabolism |
|
|
Term
|
Definition
| nonselective reuptake inhibitor (serotonin, norepinephrine, dopamine); serotonin enhances satiety, norepinephine increases metabolism |
|
|
Term
|
Definition
| also antagonizes H1 receptor |
|
|
Term
|
Definition
| blocks brain and GI nausea and vomiting centers |
|
|
